How I Prevent Viral Reactivation in High-risk Patients

Overview

Journal Blood

Publisher Elsevier

Specialty Hematology

Date 2022 Dec 9

PMID 36493341

Authors

Sanjeet S Dadwal

Genovefa A Papanicolaou

Michael Boeckh

Affiliations

Soon will be listed here.

Abstract

Preventing viral infections at an early stage is a key strategy for successfully improving transplant outcomes. Preemptive therapy and prophylaxis with antiviral agents have been successfully used to prevent clinically significant viral infections in hematopoietic cell transplant recipients. Major progress has been made over the past decades in preventing viral infections through a better understanding of the biology and risk factors, as well as the introduction of novel antiviral agents and advances in immunotherapy. High-quality evidence exists for the effective prevention of herpes simplex virus, varicella-zoster virus, and cytomegalovirus infection and disease. Few data are available on the effective prevention of human herpesvirus 6, Epstein-Barr virus, adenovirus, and BK virus infections. To highlight the spectrum of clinical practice, here we review high-risk situations that we handle with a high degree of uniformity and cases that feature differences in approaches, reflecting distinct hematopoietic cell transplant practices, such as ex vivo T-cell depletion.

Citing Articles

Virus-Specific T-Cell Therapy for the Management of Viral Infections in the Immunocompromised.

Koukoulias K, Papayanni P, Leen A, Vasileiou S Transfus Med Hemother. 2025; 52(1):5-26.

PMID: 39944414 PMC: 11813280. DOI: 10.1159/000540961.

Long-term efficacy of CMV/EBV bivirus-specific T cells for viral co-reactivation after stem cell transplantation.

Pei X, Lv M, Mo X, Sun Y, Chen Y, Yan C Chin Med J (Engl). 2025; .

PMID: 39820071 PMC: 11882268. DOI: 10.1097/CM9.0000000000003443.

Antiviral Stewardship in Transplantation.

Bonda S, Trinh S, Hand J Viruses. 2025; 16(12.

PMID: 39772192 PMC: 11680139. DOI: 10.3390/v16121884.

Applications of Biological Therapy for Latent Infections: Benefits and Risks.

Zong Y, Kamoi K, Miyagaki M, Zhang J, Yang M, Zou Y Int J Mol Sci. 2024; 25(17).

PMID: 39273134 PMC: 11394918. DOI: 10.3390/ijms25179184.

Cytomegalovirus viral load at initiation of pre-emptive antiviral therapy impacts cytomegalovirus dynamics in pediatric allogeneic hematopoietic cell transplantation recipients.

Gutierrez V, Stanek J, Ardura M, Song E Transpl Infect Dis. 2024; 26(6):e14358.

PMID: 39185743 PMC: 11666870. DOI: 10.1111/tid.14358.

References

Marty F, Maertens J, Badshah C . Letermovir Prophylaxis for Cytomegalovirus. N Engl J Med. 2018; 378(10):965. DOI: 10.1056/NEJMc1800572. View

Grant R, Weitzman S, Sherman C, Sirkin W, Petric M, Tellier R . Fulminant disseminated Varicella Zoster virus infection without skin involvement. J Clin Virol. 2001; 24(1-2):7-12. DOI: 10.1016/s1386-6532(01)00217-7. View

Torres H, McDonald G . How I treat hepatitis C virus infection in patients with hematologic malignancies. Blood. 2016; 128(11):1449-57. PMC: 6033045. DOI: 10.1182/blood-2016-05-718643. View

Lucchini G, Perales M, Veys P . Immune reconstitution after cord blood transplantation: peculiarities, clinical implications and management strategies. Cytotherapy. 2015; 17(6):711-722. DOI: 10.1016/j.jcyt.2015.03.614. View

Ciurea S, Mulanovich V, Saliba R, Bayraktar U, Jiang Y, Bassett R . Improved early outcomes using a T cell replete graft compared with T cell depleted haploidentical hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2012; 18(12):1835-44. PMC: 4320643. DOI: 10.1016/j.bbmt.2012.07.003. View

Hill J, Mayer B, Xie H, Leisenring W, Huang M, Stevens-Ayers T . The cumulative burden of double-stranded DNA virus detection after allogeneic HCT is associated with increased mortality. Blood. 2017; 129(16):2316-2325. PMC: 5399484. DOI: 10.1182/blood-2016-10-748426. View

Camargo J, Lin R, Natori Y, Anderson A, Alencar M, Wang T . Reduced immunogenicity of the adjuvanted recombinant zoster vaccine after hematopoietic cell transplant: a pilot study. Blood Adv. 2020; 4(19):4618-4622. PMC: 7556121. DOI: 10.1182/bloodadvances.2020002269. View

Erard V, Guthrie K, Varley C, Heugel J, Wald A, Flowers M . One-year acyclovir prophylaxis for preventing varicella-zoster virus disease after hematopoietic cell transplantation: no evidence of rebound varicella-zoster virus disease after drug discontinuation. Blood. 2007; 110(8):3071-7. DOI: 10.1182/blood-2007-03-077644. View

Cesaro S, Dalianis T, Rinaldo C, Koskenvuo M, Pegoraro A, Einsele H . ECIL guidelines for the prevention, diagnosis and treatment of BK polyomavirus-associated haemorrhagic cystitis in haematopoietic stem cell transplant recipients. J Antimicrob Chemother. 2017; 73(1):12-21. DOI: 10.1093/jac/dkx324. View

10.

Barrett A, Prockop S, Bollard C . Virus-Specific T Cells: Broadening Applicability. Biol Blood Marrow Transplant. 2017; 24(1):13-18. PMC: 5743764. DOI: 10.1016/j.bbmt.2017.10.004. View

11.

Hiwarkar P, Amrolia P, Sivaprakasam P, Lum S, Doss H, ORafferty C . Brincidofovir is highly efficacious in controlling adenoviremia in pediatric recipients of hematopoietic cell transplant. Blood. 2017; 129(14):2033-2037. DOI: 10.1182/blood-2016-11-749721. View

12.

Finke J, Bethge W, Schmoor C, Ottinger H, Stelljes M, Zander A . Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncol. 2009; 10(9):855-64. DOI: 10.1016/S1470-2045(09)70225-6. View

13.

Boeckh M, Nichols W, Chemaly R, Papanicolaou G, Wingard J, Xie H . Valganciclovir for the prevention of complications of late cytomegalovirus infection after allogeneic hematopoietic cell transplantation: a randomized trial. Ann Intern Med. 2015; 162(1):1-10. PMC: 4465336. DOI: 10.7326/M13-2729. View

14.

Soiffer R, Kim H, McGuirk J, Horwitz M, Johnston L, Patnaik M . Prospective, Randomized, Double-Blind, Phase III Clinical Trial of Anti-T-Lymphocyte Globulin to Assess Impact on Chronic Graft-Versus-Host Disease-Free Survival in Patients Undergoing HLA-Matched Unrelated Myeloablative Hematopoietic Cell.... J Clin Oncol. 2017; 35(36):4003-4011. PMC: 8462523. DOI: 10.1200/JCO.2017.75.8177. View

15.

Mynarek M, Ganzenmueller T, Mueller-Heine A, Mielke C, Gonnermann A, Beier R . Patient, virus, and treatment-related risk factors in pediatric adenovirus infection after stem cell transplantation: results of a routine monitoring program. Biol Blood Marrow Transplant. 2013; 20(2):250-6. DOI: 10.1016/j.bbmt.2013.11.009. View

16.

Ishiyama K, Katagiri T, Ohata K, Hosokawa K, Kondo Y, Yamazaki H . Safety of pre-engraftment prophylactic foscarnet administration after allogeneic stem cell transplantation. Transpl Infect Dis. 2011; 14(1):33-9. DOI: 10.1111/j.1399-3062.2011.00662.x. View

17.

Cassaniti I, Colombo A, Bernasconi P, Malagola M, Russo D, Iori A . Positive HCMV DNAemia in stem cell recipients undergoing letermovir prophylaxis is expression of abortive infection. Am J Transplant. 2020; 21(4):1622-1628. DOI: 10.1111/ajt.16450. View

18.

Ogata M, Takano K, Moriuchi Y, Kondo T, Ueki T, Nakano N . Effects of Prophylactic Foscarnet on Human Herpesvirus-6 Reactivation and Encephalitis in Cord Blood Transplant Recipients: A Prospective Multicenter Trial with an Historical Control Group. Biol Blood Marrow Transplant. 2018; 24(6):1264-1273. DOI: 10.1016/j.bbmt.2018.02.008. View

19.

Gentile G, Antonelli G . HBV Reactivation in Patients Undergoing Hematopoietic Stem Cell Transplantation: A Narrative Review. Viruses. 2019; 11(11). PMC: 6893755. DOI: 10.3390/v11111049. View

20.

Sedlacek P, Petterson T, Robin M, Sivaprakasam P, Vainorius E, Brundage T . Incidence of Adenovirus Infection in Hematopoietic Stem Cell Transplantation Recipients: Findings from the AdVance Study. Biol Blood Marrow Transplant. 2018; 25(4):810-818. DOI: 10.1016/j.bbmt.2018.12.753. View